MainSleaze

As with Proteogenix, here’s another bunch who figure the act of publishing a scientific paper serves as a form of granting consent to be added to all sorts of mailing lists.

Spamming IP: mail.scbt.com [64.166.169.131]

Spam headers:

Return-Path: <santacruzbiotechnology@scbt.com>
Received: from scbt.com (mail.scbt.com [64.166.169.131])
        by x (8.14.5/8.14.5) with ESMTP id x
        for <x>; Wed, 8 Feb 2012 15:5x:xx +0200
Received: from [192.168.2.104] (HELO localhost)
  by scbt.com (CommuniGate Pro SMTP 5.3.4)
  with ESMTP id x for x; Wed, 08 Feb 2012 05:5x:xx -0800
Mime-Version: 1.0 
Content-Type: text/html;
        charset="US-ASCII";
        format=flowed
Subject:281 New Antibodies Available from SCBT
To: x
CC: 
From: Santa Cruz Biotechnology<santacruzbiotechnology@scbt.com>
Message-ID:<x@scbt.com>
Date: Wed, 08 Feb 2012 05:5x:xx -0800

Human-readable spam contents: None. The message has no plaintext part at all. Here’s the end of the HTML part:

Copyright © 2012 Santa Cruz Biotechnology, Inc. Santa Cruz Biotechnology, Inc. and the Santa Cruz Biotechnology, Inc. logo are registered trademarks of Santa Cruz Biotechnology, Inc. All content contained in this website is property of Santa Cruz Biotechnology, Inc. and may be used only with the expressed written permission of Santa Cruz Biotechnology, Inc. All rights reserved. Santa Cruz Biotechnology, Inc. is located at 2145 Delaware Avenue, Santa Cruz, CA 95060 USA Email: webmaster@scbt.com

If you desire to not receive our e-mail bulletins at x, simply unsubscribe or forward this email message to webmaster@scbt.com.

Santa Cruz Biotechnology, Inc.